BidaskClub upgraded shares of NeuroDerm Ltd. (NASDAQ:NDRM) from a sell rating to a hold rating in a research report report published on Tuesday, July 25th.
Several other equities analysts also recently issued reports on the stock. Raymond James Financial, Inc. downgraded shares of NeuroDerm from an outperform rating to a market perform rating and set a $39.00 price target for the company. in a research note on Monday, July 24th. Deutsche Bank AG started coverage on shares of NeuroDerm in a research note on Friday, July 21st. They set a buy rating and a $47.00 target price for the company. Zacks Investment Research downgraded shares of NeuroDerm from a hold rating to a sell rating in a research note on Saturday, July 15th. Roth Capital set a $33.00 target price on shares of NeuroDerm and gave the stock a buy rating in a research note on Wednesday, June 14th. Finally, CIBC upgraded shares of NeuroDerm from a market perform rating to an outperform rating and set a $42.00 price target for the company in a report on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. NeuroDerm presently has an average rating of Hold and an average price target of $44.13.
NeuroDerm (NDRM) remained flat at $38.60 during mid-day trading on Tuesday. The company’s stock had a trading volume of 1,108,706 shares. The firm’s 50 day moving average is $33.65 and its 200-day moving average is $27.49. The stock’s market capitalization is $1.02 billion. NeuroDerm has a one year low of $15.20 and a one year high of $38.85.
NeuroDerm (NASDAQ:NDRM) last released its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.13. On average, equities analysts forecast that NeuroDerm will post ($2.03) EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Menora Mivtachim Holdings LTD. boosted its position in NeuroDerm by 18.6% in the second quarter. Menora Mivtachim Holdings LTD. now owns 808,073 shares of the biotechnology company’s stock valued at $24,161,000 after buying an additional 126,517 shares during the period. Wells Fargo & Company MN boosted its position in NeuroDerm by 55,181.2% in the second quarter. Wells Fargo & Company MN now owns 373,148 shares of the biotechnology company’s stock valued at $11,157,000 after buying an additional 372,473 shares during the period. Senzar Asset Management LLC boosted its position in NeuroDerm by 10.4% in the second quarter. Senzar Asset Management LLC now owns 357,400 shares of the biotechnology company’s stock valued at $10,686,000 after buying an additional 33,700 shares during the period. Nexthera Capital LP purchased a new position in NeuroDerm during the first quarter valued at $7,646,000. Finally, OppenheimerFunds Inc. purchased a new position in NeuroDerm during the first quarter valued at $7,588,000. Hedge funds and other institutional investors own 52.82% of the company’s stock.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.